Literature DB >> 8403204

Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer.

S Zhong1, A H Wyllie, D Barnes, C R Wolf, N K Spurr.   

Abstract

Mammalian cytosolic glutathione S-transferases (GSTs; EC 2.5.1.18) form a supergene family consisting of four distinct families, named alpha, mu, pi and theta. In humans one member of the mu class gene family (GSTM1) has been shown to be polymorphic and is only expressed in 55-60% of individuals. Previous studies have shown a possible link with the null phenotype and susceptibility to cancer, in particular to lung cancer. In this study we genotyped individuals with breast, bladder and colorectal cancer. A total of 490 individuals with cancer were studied, and consisted of 97 bladder, 197 breast and 196 colorectal cancers. No significant differences were observed in the frequency of nulled individuals in bladder or breast cancer patients when compared with a control population of 225 individuals. However, a significant excess of nulled individuals were seen in colorectal cancer: 56.1% compared with the control group value of 41.8%. This was shown to be highly significant depending on the site of the tumours and > 70% of individuals with a tumour in the proximal colon were GSTM1 nulled. This is an approximately 2-fold increase in colon cancer risk in these individuals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403204     DOI: 10.1093/carcin/14.9.1821

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  66 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Impairment of colour vision in workers exposed to organic solvents.

Authors:  S Semple; F Dick; A Osborne; J W Cherrie; A Soutar; A Seaton; N Haites
Journal:  Occup Environ Med       Date:  2000-09       Impact factor: 4.402

Review 3.  Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.

Authors:  Stephanie M Tortorella; Simon G Royce; Paul V Licciardi; Tom C Karagiannis
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

4.  Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.

Authors:  Peter A C 't Hoen; Ruud Out; Jan N M Commandeur; Nico P E Vermeulen; F H D van Batenburg; Muthiah Manoharan; Theo J C van Berkel; Erik A L Biessen; Martin K Bijsterbosch
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

5.  Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride monomer-exposed workers.

Authors:  Luc Fontana; Marie-Jeanne Marion; Sylvie Ughetto; Pierre Catilina
Journal:  J Hum Genet       Date:  2006-09-15       Impact factor: 3.172

Review 6.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

7.  Assignment of the mu-class glutathione S-transferase gene (hGSTYBX) to Syrian hamster chromosome 15 by FISH.

Authors:  F Maggouta; S A Li; J J Li; J S Norris
Journal:  Mamm Genome       Date:  1996-06       Impact factor: 2.957

Review 8.  Studying environmental influences and breast cancer risk: suggestions for an integrated population-based approach.

Authors:  R Millikan; E DeVoto; B Newman; D Savitz
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

9.  Dietary isothiocyanates, glutathione S-transferase M1 (GSTM1), and lung cancer risk in African Americans and Caucasians from Los Angeles County, California.

Authors:  Catherine L Carpenter; Mimi C Yu; Stephanie J London
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

10.  Serum glutathione transferase does not respond to indole-3-carbinol: A pilot study.

Authors:  Daniel R McGrath; Hamid Frydoonfar; Joshua J Hunt; Chris J Dunkley; Allan D Spigelman
Journal:  Ther Clin Risk Manag       Date:  2010-05-25       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.